Comparison of Olmesartan Medoxomil Versus Amlodipine Besylate on Regression of Ventricular and Vascular Hypertrophy

American Journal of Cardiology

Volumn 104, Issue 3, 2009, Pages 359-365

  Rosendorff, Clive ^a   Dubiel, Robert ^b   Xu, Jianbo ^b   Chavanu, Kathleen J ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b DAIICHI SANKYO INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN; TERAZOSIN;

ADULT; ARTERY COMPLIANCE; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BLOOD VESSEL HYPERTROPHY; CAROTID ARTERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DOPPLER FLOWMETRY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; ECHOCARDIOGRAPHY; ECHOGRAPHY; FATIGUE; FEMALE; FEMORAL ARTERY; HEART LEFT VENTRICLE COMPLIANCE; HEART LEFT VENTRICLE MASS; HEART VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPERTROPHY; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINITIS; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION;

AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIASTOLE; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; IMIDAZOLES; MALE; MIDDLE AGED; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 67651122005     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.03.042     Document Type: Article

References (12)

1. Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G., Grassi G., Heagerty A.M., Kjeldsen S.E., Laurent S., Narkiewicz K., Ruilope L., Rynkiewicz A., Schmieder R.E., Struijker Boudier H.A., Zanchetti A., Vahanian A., Camm J., De Caterina R., Dean V., Dickstein K., Filippatos G., Funck-Brentano C., Hellemans I., Kristensen S.D., McGregor K., Sechtem U., Silber S., Tendera M., Widimsky P., Zamorano J.L., Kjeldsen S.E., Erdine S., Narkiewicz K., Kiowski W., Agabiti-Rosei E., Ambrosioni E., Cifkova R., Dominiczak A., Fagard R., Heagerty A.M., Laurent S., Lindholm L.H., Mancia G., Manolis A., Nilsson P.M., Redon J., Schmieder R.E., Struijker-Boudier H.A., Viigimaa M., Filippatos G., Adamopoulos S., Agabiti-Rosei E., Ambrosioni E., Bertomeu V., Clement D., Erdine S., Farsang C., Gaita D., Kiowski W., Lip G., Mallion J.M., Manolis A.J., Nilsson P.M., O'Brien E., Ponikowski P., Redon J., Ruschitzka F., Tamargo J., van Zwieten P., Viigimaa M., Waeber B., Williams B., and Zamorano J.L. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28 (2007) 1462-1536
2. Liebson P.R. Calcium channel blockers in the spectrum of antihypertensive agents. Expert Opin Pharmacother 7 (2006) 2385-2401
3. Reudelhuber T.L., Bernstein K.E., and Delafontaine P. Is angiotensin II a direct mediator of left ventricular hypertrophy?. Time for another look. Hypertension 49 (2007) 1196-1201
4. Mizuno M., Sada T., Ikeda M., Fukuda N., Miyamoto M., Yanagisawa H., and Koike H. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol 285 (1995) 181-188
5. Devereux R.B., Dahlof B., Gerdts E., Boman K., Nieminen M.S., Papademetriou V., Rokkedal J., Harris K.E., Edelman J.M., and Wachtell K. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 110 (2004) 1456-1462
6. Dahlof B., Pennert K., and Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies. Am J Hypertens 5 (1992) 95-110
7. Gaudio C., Ferri F.M., Giovannini M., Pannarale G., Puddu P.E., Vittore A., Fera M.S., Vizza C.D., and Fedele F. Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy. J Cardiovasc Pharmacol 42 (2003) 622-628
8. Libhaber E.N., Libhaber C.D., Candy G.P., Sliwa K., Kachope J., Hlatshwayo N.M., Puane M.O., Woodiwiss A.J., Norton G.R., Essop M.R., and Sareli P. Effect of slow-release indapamide and perindopril compared with amlodipine on 24-hour blood pressure and left ventricular mass in hypertensive patients of African ancestry. Am J Hypertens 17 (2004) 428-432
9. Mitsunami K., Inoue S., Maeda K., Endoh S., Takahashi M., Okada M., Sugihara H., and Kinoshita M. Three-month effects of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension. Cardiovasc Drugs Ther 12 (1998) 469-474
10. Levy D., Savage D.D., Garrison R.J., Anderson K.M., Kannel W.B., and Castelli W.P. Echocardiographic criteria for left ventricular hypertrophy: the Framingham heart study. Am J Cardiol 59 (1987) 956-960
11. Wright Jr. J.T. Profile of systemic hypertension in black patients. Am J Cardiol 61 (1988) 41H-45H
12. Julius S., Alderman M.H., Beevers G., Dahlof B., Devereux R.B., Douglas J.G., Edelman J.M., Harris K.E., Kjeldsen S.E., Nesbitt S., Randall O.S., and Wright Jr. J.T. Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. J Am Coll Cardiol 43 (2004) 1047-1055